Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Cogstate Ltd ( (AU:CGS) ).
Cogstate Ltd, a specialist in CNS clinical trial endpoints and digital cognitive testing, continues to expand its role in neuroscience research by supplying technology and services that improve the accuracy and actionability of cognitive data. The company also serves healthcare providers and consumers with validated digital tools designed to streamline cognitive screening in primary care.
In its third quarter to 31 March 2026, Cogstate reported executed sales contracts of $25.4 million, lifting the year-to-date total to $67.1 million and underpinning a growing revenue backlog. Contracted revenue for FY26 has reached $56.0 million, already exceeding FY25 total revenue, while FY27 contracted revenue has risen to $35.6 million, signaling sustained demand across CNS indications and improved earnings visibility for stakeholders.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is a global Central Nervous System endpoint innovations company that partners with pharmaceutical and biotechnology firms to support complex neuroscience clinical trials. Its offerings include digital cognitive assessments, data quality programs and advanced analytics, and it also targets the healthcare market with brief, self-administered cognitive tests for primary care use.
Average Trading Volume: 181,498
Technical Sentiment Signal: Buy
Current Market Cap: A$364.2M
See more data about CGS stock on TipRanks’ Stock Analysis page.